醛固酮作为主动脉夹层的独立危险因素的前瞻性多中心观察性研究

注册号:

Registration number:

ChiCTR2500113607 

最近更新日期:

Date of Last Refreshed on:

2025-12-01 14:57:26 

注册时间:

Date of Registration:

2025-12-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

醛固酮作为主动脉夹层的独立危险因素的前瞻性多中心观察性研究

Public title:

A Prospective, Multicenter, Observational Study of Aldosterone as an Independent Risk Factor for Aortic Dissection

注册题目简写:

English Acronym:

研究课题的正式科学名称:

醛固酮作为主动脉夹层的独立危险因素的前瞻性多中心观察性研究

Scientific title:

A Prospective, Multicenter, Observational Study of Aldosterone as an Independent Risk Factor for Aortic Dissection

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

何杨燕 

研究负责人:

何杨燕 

Applicant:

He Yangyan  

Study leader:

He Yangyan  

申请注册联系人电话:

Applicant telephone:

+86 137 3813 3232

研究负责人电话:

Study leader's
telephone:

+86 137 3813 3232

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

15140332@zju.edu.com

研究负责人电子邮件:

Study leader's E-mail:

15140332@zju.edu.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国浙江省杭州市上城区庆春路79号

研究负责人通讯地址:

中国浙江省杭州市上城区庆春路79号

Applicant address:

No. 79, Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China

Study leader's address:

No. 79, Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China

申请注册联系人邮政编码:

Applicant postcode:

310003

研究负责人邮政编码:

Study leader's postcode:

310003

申请人所在单位:

浙江大学医学院附属第一医院

Applicant's institution:

The First Affiliated Hospital, Zhejiang University School of Medicine

研究负责人所在单位:

浙江大学医学院附属第一医院

Affiliation of the Leader:

The First Affiliated Hospital, Zhejiang University School of Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

浙大一院伦审2025研第1194号-快

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

浙江大学附属第一医院IIT伦理审查委员会

Name of the ethic committee:

Clinical Research Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-10-29 00:00:00

伦理委员会联系人:

厉有名

Contact Name of the ethic committee:

Li Youming

伦理委员会联系地址:

中国浙江省杭州市上城区庆春路79号

Contact Address of the ethic committee:

No. 79, Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 571 8723 3418

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

浙江大学医学院附属第一医院

Primary sponsor:

The First Affiliated Hospital, Zhejiang University School of Medicine

研究实施负责(组长)单位地址:

中国浙江省杭州市上城区庆春路79号

Primary sponsor's address:

No. 79, Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

杭州

Country:

China

Province:

Zhejiang

City:

Hanghzou

单位(医院):

浙江大学医学院附属第一医院

具体地址:

中国浙江省杭州市上城区庆春路79号

Institution
hospital:

The First Affiliated Hospital, Zhejiang University School of Medicine

Address:

No. 79, Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China

经费或物资来源:

Source(s) of funding:

None

研究疾病:

主动脉夹层  

Target disease:

Aortic Dissection

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

本研究旨在以前瞻性、多中心、配对队列设计,系统评估醛固酮水平升高能否作为高血压人群发生主动脉夹层的独立危险因素。研究结果有望为主动脉夹层的风险分层和早期预防提供新的生物标志物和干预靶点。  

Objectives of Study:

This study aims to systematically evaluate, through a prospective, multicenter, matched-pair cohort design, whether elevated aldosterone levels can serve as an independent risk factor for aortic dissection in the hypertensive population. The findings are expected to provide a new biomarker and intervention target for the risk stratification and early prevention of aortic dissection.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

病例组排除标准: 1)创伤性主动脉夹层; 2)医源性主动脉夹层; 3)需急诊手术的主动脉夹层; 4)已知患有遗传性结缔组织病,如马凡综合征、Loeys-Dietz综合征、血管性Ehlers-Danlos综合征等; 5)已知的嗜铬细胞瘤、库欣综合征等其他继发性高血压原因; 6)严重肾功能不全(eGFR < 30 ml/min/1.73m²),因其可能影响醛固酮和肾素水平; 7)严重肝功能损害(Child-Pugh C级); 8)妊娠期或哺乳期妇女; 9)无法配合完成研究或提供完整病史资料者。 对照组排除标准: 1)任何主动脉疾病史,包括主动脉夹层、主动脉瘤或主动脉壁间血肿; 2) 严重心血管疾病史,如近期(6个月内)心肌梗死、不稳定性心绞痛、严重心力衰竭(NYHA IV级); 3)已知的继发性高血压原因,如肾血管性高血压、嗜铬细胞瘤、库欣综合征等; 4) 严重肾功能不全(eGFR < 30 ml/min/1.73m²)或严重肝功能损害; 5)妊娠期或哺乳期妇女; 6)无法配合完成研究或提供完整病史资料者。

Exclusion criteria:

Exclusion criteria for the case group: 1) Traumatic aortic dissection; 2) Iatrogenic aortic dissection; 3) Aortic dissection requiring emergency surgery; 4) Known diagnosis of inherited connective tissue diseases, such as Marfan syndrome, Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome, etc.; 5) Known secondary causes of hypertension, such as pheochromocytoma, Cushing's syndrome, etc.; 6) Severe renal insufficiency (eGFR < 30 ml/min/1.73m²), as it may affect aldosterone and renin levels; 7) Severe hepatic impairment (Child-Pugh class C); 8) Pregnant or lactating women; 9) Inability to cooperate with the study or provide complete medical history data. Exclusion criteria for the control group: 1) Any history of aortic diseases, including aortic dissection, aortic aneurysm, or aortic intramural hematoma; 2) History of severe cardiovascular diseases, such as recent (within 6 months) myocardial infarction, unstable angina, or severe heart failure (NYHA class IV); 3) Known secondary causes of hypertension, such as renovascular hypertension, pheochromocytoma, Cushing's syndrome, etc.; 4) Severe renal insufficiency (eGFR < 30 ml/min/1.73m²) or severe hepatic impairment; 5) Pregnant or lactating women; 6) Inability to cooperate with the study or provide complete medical history data.

研究实施时间:

Study execute time:

From 2026-01-01 00:00:00 To 2028-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-01-01 00:00:00 To 2027-12-31 00:00:00

干预措施:

Interventions:

组别:

病例组

样本量:

180

Group:

Case group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

对照组

样本量:

360

Group:

Control group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

浙江省台州医院 

单位级别:

三甲 

Institution
hospital:

Taizhou Hospital of Zhejiang Province

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

杭州 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

宁波市第二医院 

单位级别:

三甲 

Institution
hospital:

Ningbo Second Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

温州医科大学附属第一医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of Wenzhou Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

衢州市人民医院 

单位级别:

三甲 

Institution
hospital:

People's Hospital of Quzhou

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

浙江大学医学院附属第四医院 

单位级别:

三甲 

Institution
hospital:

The Fourth Affiliated Hospital of Zhejiang University School of Medicine?

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

金华市中心医院 

单位级别:

三甲 

Institution
hospital:

Jinhua Maternal and Child Health Care Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

东阳市人民医院 

单位级别:

三甲 

Institution
hospital:

Dongyang People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

宁波市医疗中心李惠利医院 

单位级别:

三甲 

Institution
hospital:

Ningbo Medical Center Li Huili Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

醛固酮水平与主动脉夹层发生风险的危险度

指标类型:

主要指标

Outcome:

Risk Measure for Aldosterone Levels and Aortic Dissection

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不同危险因素的分层研究,保护性别、年龄、IBM、吸烟、疾病史等

指标类型:

次要指标

Outcome:

Stratified Analysis and Adjustment for Risk Factors, Including Sex, Age, BMI, Smoking, and Medical History

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

比较术前术后醛固酮水平的变化

指标类型:

次要指标

Outcome:

To compare aldosterone levels before and after surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

None

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-12-01 14:57:21